======= GTF2IRD1 ======= == Gene Information == * **Official Symbol**: GTF2IRD1 * **Official Name**: GTF2I repeat domain containing 1 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9569|9569]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q9UHL9|Q9UHL9]] * **Interactions**: [[https://thebiogrid.org/search.php?search=GTF2IRD1&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20GTF2IRD1|Open PubMed]] * **OMIM**: [[https://omim.org/entry/604318|Open OMIM]] == Function Summary == * **Entrez Summary**: The protein encoded by this gene contains five GTF2I-like repeats and each repeat possesses a potential helix-loop-helix (HLH) motif. It may have the ability to interact with other HLH-proteins and function as a transcription factor or as a positive transcriptional regulator under the control of Retinoblastoma protein. This gene plays a role in craniofacial and cognitive development and mutations have been associated with Williams-Beuren syndrome, a multisystem developmental disorder caused by deletion of multiple genes at 7q11.23. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2010]. * **UniProt Summary**: May be a transcription regulator involved in cell-cycle progression and skeletal muscle differentiation. May repress GTF2I transcriptional functions, by preventing its nuclear residency, or by inhibiting its transcriptional activation. May contribute to slow-twitch fiber type specificity during myogenesis and in regenerating muscles. Binds troponin I slow-muscle fiber enhancer (USE B1). Binds specifically and with high affinity to the EFG sequences derived from the early enhancer of HOXC8 (By similarity). {ECO:0000250, ECO:0000269|PubMed:11438732}. |GTF2I| |transition between slow and fast fiber| |regulation of skeletal muscle adaptation| |regulation of muscle adaptation| |regulation of muscle system process| |transcription by RNA polymerase II| |regulation of system process| |transcription, DNA-templated| |nucleic acid-templated transcription| |RNA biosynthetic process| |DNA-binding transcription factor activity| |nucleobase-containing compound biosynthetic process| |heterocycle biosynthetic process| |aromatic compound biosynthetic process| |organic cyclic compound biosynthetic process| |DNA binding| |DNA-binding transcription factor activity, RNA polymerase II-specific| |cellular nitrogen compound biosynthetic process| |RNA metabolic process| |cellular macromolecule biosynthetic process| |macromolecule biosynthetic process| |gene expression| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|-2| |[[:results:exp95|BI-2536 0.0042μM R03 exp95]]|1.8| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 0/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 10635 * **Expression level (log2 read counts)**: 4.68 {{:chemogenomics:nalm6 dist.png?nolink |}}